Discovery of tumoricidal DNA oligonucleotides by effect-directedin-vitroevolution

Abstract

Our current model of drug discovery is challenged by the relative ineffectiveness of drugs against highly variable and rapidly evolving diseases and their relatively high incidence of adverse effects due to poor selectivity. Here we describe a robust and reproducible platform which could potentially address these limitations. The platform enables rapid, de-novo discovery of DNA aptamers evolved in-vitro to exert specific biological effects on target cells. Unlike conventional aptamers, which are selected by their ligand binding capacity, this platform is driven directly by therapeutic effect and selectivity towards target vs negative target cells. The process could, therefore, operate without any a-priori knowledge (e.g. mutations, biomarker expression, or known drug resistance) of the target. We report the discovery of DNA aptamers with direct and selective cytotoxicity towards several tumor cell lines as well as primary, patient-derived solid and hematological tumors, some with chemotherapy resistance. Aptamers discovered by this platform exhibited favorable biodistribution in animals, persistence in target tumors up to 48 hours after injection, and safety in human blood. These aptamers showed remarkable efficacy in-vivo as well as ex-vivo in freshly obtained, 3D cultured human tumors resistant to multiple chemotherapies. With further improvement, these findings could lead to a drug discovery model which is target-tailored, mechanism-flexible, and nearly on-demand.

Ab-initiodiscovery of tumoricidal oligonucleotides in a DNA sequencing machine

“…Moreover, we extended our approach from cell binding to cellular effects, using the apoptosis of tumor cells as a test case. We recently described the discovery of tumoricidal aptamers by effect-direct in-vitro evolution 31 . Here we demonstrate a variation on this technique, that utilizes the physical chips produced by Illumina sequencing in order to identify tumoricidal aptamers specific to patient-derived cells, with extremely promising results.…”